Αποτελέσματα Αναζήτησης
4 Ιουν 2020 · The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen-degradation products, whereas abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations.
24 Νοε 2020 · Although the infection is frequently asymptomatic or associated with mild symptoms, in a small proportion of patients it can produce an intense inflammatory and prothrombotic state that can lead to acute respiratory distress syndrome, multiple organ failure, and death.
23 Ιουλ 2020 · The coagulopathy associated with COVID-19 is characterized by mild thrombocytopenia, slight prolongation of the prothrombin time, high levels of D-dimer, and elevated levels of fibrinogen, factor VIII, and von Willebrand factor.
21 Ιουλ 2022 · COVID-19 infection is a thromboinflammatory disorder, and the primary prothrombotic features are termed “COVID-19-associated coagulopathy.” 3 Evidence suggests that this is linked to the inflammatory response against SARS-CoV-2, with complex interactions between the viral, immune, and inflammatory systems and coagulation pathways at local and sy...
1 Αυγ 2022 · The aim of the study was to investigate the role of coagulation parameters namely Prothrombin concentration (PC), activated Partial thromboplastin Time (aPTT), D-Dimer (DD), Anti Thrombin III...
11 Μαΐ 2020 · The most typical finding in patients with COVID-19 and coagulopathy is an increased D-dimer concentration, a relatively modest decrease in platelet count, and a prolongation of the prothrombin time. In a series 6 of 1099 patients with COVID-19 from China, elevated D-dimer (>0·5 mg/L) was found in 260 (46%) of 560 patients.
15 Φεβ 2022 · Coagulation disorders are common in COVID-19 and are associated with the severity of the disease. With the incidence of a viral disease following inflammatory responses, an imbalance in pro-coagulant and anticoagulant mechanisms occurs, with endothelial dysfunction playing a major role [3].
